京新药业(002020) - 2019 Q3 - 季度财报

Financial Performance - Operating revenue for the period reached CNY 936,980,485.80, representing a year-on-year growth of 13.77%[9] - Net profit attributable to shareholders increased by 27.56% to CNY 163,197,581.01 for the quarter[9] - The total profit for the period was CNY 568.52 million, an increase of 44.89% compared to the same period last year, mainly due to growth in main business income[31] - Net profit for the period was CNY 489.44 million, an increase of 43.98% compared to the same period last year, primarily due to the increase in total profit[31] - Investment income for the period was CNY 94.89 million, an increase of 76.90% compared to the same period last year, mainly due to increased financial investment returns[30] - Other income for the period was CNY 21.28 million, an increase of 44.63% compared to the same period last year, primarily due to government subsidies[28] - The total profit for the current period was ¥579,370,073.35, up from ¥326,551,792.28 in the previous period, representing an increase of approximately 77.2%[84] - Net profit attributable to the parent company was ¥488,972,456.62, compared to ¥341,006,983.04 in the same period last year, reflecting a year-on-year increase of about 43.5%[81] Earnings and Shareholder Information - Basic earnings per share increased by 41.18% to CNY 0.24[9] - The company reported a total of 35,496 shareholders at the end of the reporting period[13] - The top shareholder, Lü Gang, holds 20.55% of the shares, totaling 148,997,296 shares[14] - Basic and diluted earnings per share for the current period were both ¥0.24, up from ¥0.17 in the previous period[71] - Earnings per share (basic and diluted) for the current period were both ¥0.71, up from ¥0.47 in the same period last year, reflecting a growth of approximately 51.1%[81] Assets and Liabilities - Total assets increased by 9.11% to CNY 5,446,582,277.25 compared to the end of the previous year[9] - Current liabilities increased to CNY 1,638,363,139.53 from CNY 1,341,005,665.56 year-on-year[52] - Total liabilities amounted to CNY 1,713,612,688.60, up from CNY 1,418,374,285.05[52] - Total assets reached CNY 5,446,582,277.25, an increase from CNY 4,991,769,097.50[49] - The company reported a total non-current asset value of CNY 1,956,235,985.88[112] - The total liabilities increased to ¥1,293,304,523.01 from ¥1,028,301,308.22, representing a rise of 25.8%[62] Cash Flow - Cash flow from operating activities showed a net increase of 12.52% to CNY 101,326,127.88[9] - Operating cash inflow for the current period reached ¥3,184,155,740.14, a 25.3% increase from ¥2,542,091,730.54 in the previous period[88] - Net cash flow from operating activities was ¥415,879,809.68, up 64.5% from ¥252,623,991.90 year-on-year[91] - Cash inflow from investment activities totaled ¥2,242,089,867.94, a decrease of 6.3% compared to ¥2,392,186,517.17 in the previous period[91] - Cash outflow from financing activities was ¥360,935,551.82, down 34.7% from ¥553,627,108.89 year-on-year[94] Share Repurchase and Equity - The company did not engage in any repurchase agreements during the reporting period[17] - The company repurchased a total of 38.25 million shares, accounting for 5.28% of the total share capital, with a total payment of CNY 378.17 million[36] - The company’s undistributed profits at the end of the period were CNY 1.13 billion, an increase of 33.58% compared to the beginning of the year, mainly due to increased profits[26] Research and Development - Research and development expenses increased to ¥81,247,157.55, compared to ¥64,144,055.32, marking a growth of 26.7%[65] - Research and development expenses increased to ¥31,620,000, up from ¥27,535,108, reflecting a growth of 14.5%[72] - Research and development expenses amounted to ¥81,762,166.37, slightly higher than ¥79,938,913.39 in the previous period, showing an increase of about 2.3%[84] Market Strategy - The company plans to continue expanding its market presence and investing in new product development to drive future growth[65]